Bipolar disorder

Handbook of Clinical Neurology

Volumn 106, Issue , 2012, Pages 251-263

  Smith, Daniel J ^a   Whitham, Elizabeth A ^b   Ghaemi, S Nassir ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861143628     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52002-9.00015-2     Document Type: Chapter

References (124)

1. Adler C.M., Schmithorst V., Wilke M., et al. Abnormal frontal white matter tracts in bipolar disorder: a diffusion tensor imaging study. Bipolar Disord 2004, 6:197-203.
2. Akiskal H.S., Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 1999, 22:517-534. vii.
3. Altshuler L.L., Grieder T., Curran J., et al. Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: An MRI study demonstrating neuroanatomic specificity. Arch Gen Psychiatry 1998, 55:663-664.
4. Altshuler L., Suppes T., Black D., et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003, 160:1252-1262.
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th edn.
6. Anand A., Oren D., Berman R. Lamotrigine treatment of lithium failure in outpatient mania: a double-blind, placebo-controlled trial 1999, Third International Bipolar Conference. Munksgaard, In.
7. Angst J., Marneros A. Bipolarity from ancient to modern times: conception, birth and rebirth. J Affect Disord 2001, 67:3-19.
8. Bachmann R.F., Gould T.D., Manji H.K. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005, 32:173-202.
9. Badner J.A., Gershon E.S. Meta-analysis of whole genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002, 7:405-411.
10. Baldessarini R., Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000, 57:187-190.
11. Baxter L.R., Phelps M.E., Mazziotta J.C., et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989, 46:243-250.
12. Bowden C. New concepts in mood stabilization: for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998, 19:194-199.
13. Bowden C., Brugger A., Swann A., et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994, 271:918-924.
14. Bowden C.L., Calabrese J., McElroy S., et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000, 57:481-489.
15. Brady K., Sonne S. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995, 56:19-24.
16. Bremner J.D., Anderson E.R., Staib L.H., et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000, 157:115-118.
17. Brown A.S., Lin S.P., Neugebauer R., et al. Increased risk of affective disorders in males after second trimester prenatal exposure to the Dutch hunger winter of 1944-45. Br J Psychiatry 1995, 166:601-606.
18. Calabrese J.R., Suppes T., Bowden C.L., et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000, 61:841-850.
19. Calabrese J., Bowden C.L., Sachs G., et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003, 64:1013-1024.
20. Calabrese J.R., Shelton M.D., Rapport D.J., et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005, 162:2152-2161.
21. Calabrese J.R., Keck P.E., Macfadden W., et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360.
22. Cassano G.B., Rucci P., Frank E., et al. The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry 2004, 161:1264-1269.
23. Chen Y.S., Detera-Wadleigh S.D., Schulze T.G., et al. Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33. Mol Psychiatry 2004, 9:87-92.
24. Chumakov I., Blumenfeld M., Guerassimenko O., et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002, 99:13675-13680.
25. Coffey C.E., Weiner R.D., Parashos I.A., et al. Quantitative cerebral anatomy in depression. A controlled magnetic resonance imaging study. Arch Gen Psychiatry 1993, 50:7-16.
26. Colom F., Martinez-Aran A., Reinares M., et al. A randomized single-blind trial of the efficacy of group psychoeducation in the prevention of relapses in remitted bipolar patients 2002, Annual Meeting of the American Psychiatric Association. Philadelphia, PA, In.
27. Craddock N., Jones I. Genetics of bipolar disorder. J Med Genet 1999, 36:585-594.
28. Craddock N., Owen M.J. The beginning of the end for the Kraepelinian dichotomy. Br J Psychiatry 2005, 186:364-366.
29. Davis L.L., Bartolucci A., Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005, 85:259-266.
30. de Asis J.M., Alexopoulos G.S., Pan H., et al. Hippocampal and anterior cingulate activation deficits in patients with geriatric depression. Am J Psychiatry 2001, 158:1321-1323.
31. Devon R.S., Anderson S., Teague P.W., et al. Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. Psychiatr Genet 2001, 11:71-78.
32. Dunner D., Fieve R. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974, 30:229-233.
33. Elliott R., Rogers R.D., O'Leary D.A., et al. Prefrontal dysfunction in depressed patients performing a complex planning task: a study using positron emission tomography. Psychol Med 1997, 24:931-942.
34. Fanelli R.J., McNamara J.O. Effects of age on kindling and kindled seizure-induced increase of benzodiazepine receptor binding. Brain Res 1986, 362:17-22.
35. Ferrier I.N., Stanton B.R., Kelly T.P., et al. Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry 1999, 175:246-251.
36. Frangou S., Raymont V., Bettany D. The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disord 2002, 4:378-385.
37. Ghaemi S.N. Mood Disorders: A Practical Guide 2003, Lippincott, Williams, and Wilkins, Philadelphia.
38. Ghaemi S.N., Goodwin F.K. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. J Affect Disord 2001, 65:281-287.
39. Ghaemi S.N., Boiman E.E., Goodwin F.K. Kindling and second messengers: an approach to the neurobiology of recurrence in bipolar disorder. Biol Psychiatry 1999, 45:137-144.
40. Ghaemi S.N., Boiman E.E., Goodwin F.K. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000, 61:804-808.
41. Ghaemi S.N., Boiman E.E., Goodwin F.K. Insight and outcome in bipolar, unipolar, and anxiety disorders. Compr Psychiatry 2000, 41:167-171.
42. Ghaemi S.N., Lenox M.S., Baldessarini R.J. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001, 62:565-569.
43. Ghaemi S.N., Ko J.Y., Goodwin F.K. " Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002, 47:125-134.
44. Ghaemi S.N., Hsu D.J., Soldani F., et al. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003, 5:421-433.
45. Ghaemi S.N., Pardo T.B., Hsu D.J. Strategies for preventing the recurrence of bipolar disorder. J Clin Psychiatry 2004, 65:16-23.
46. Gijsman H.J., Geddes J.R., Rendell J.M., et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004, 161:1537-1547.
47. Glahn D.C., Niendam T.A., Escamilla M.A. The feasibility of neuropsychological endophenotypes in the search for genes associated with bipolar affective disorder. Bipolar Disord 2004, 6:171-182.
48. Goldberg J.F., Harrow M. Kindling in bipolar disorders: a longitudinal follow-up study. Biol Psychiatry 1994, 35:70-72.
49. Goodwin F., Jamison K. Manic Depressive Illness 1990, Oxford University Press, New York.
50. Goodwin G.M., Dougall N., Ross M., et al. State changes in brain activity shown by the uptake of 99mTc-exametazime with single photon emission tomography in major depression before and after treatment. J Affect Disord 1993, 29:243-253.
51. Green E., Craddock N. Brain-derived neurotrophic factor as a potential risk locus for bipoolar disorder: evidence, limitations and implications. Curr Psychiatry Rep 2003, 5:469-476.
52. Green E.K., Macgregor S., Hyde S., et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. Br J Psychiatry 2006, 188:21-25.
53. Gyulai L., Bowden C.L., McElroy S.L., et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003, 28:1374-1382.
54. Haldane M., Frangou S. New insights help define the pathophysiology of bipolar affective disorder: neuroimaging and neuropathology findings. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:943-960.
55. Harvey P.D. Defining and achieving recovery from bipolar disorder. J Clin Psychiatry 2006, 67:14-18. discussion 36-42.
56. Hattori E., Badner J.A., Bonner T.I., et al. Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am J Hum Genet 2003, 72:1131-1140.
57. Haznedar M.M., Roversi F., Pallanti S., et al. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. Biol Psychiatry 2005, 57:733-742.
58. Henry M., Moore C., Breeze J., et al. A comparison of brain lithium levels on lithonate versus sustained release lithium using MRS 2000, Collegium Internationale Psychopharmacologicum. Brussels, Belgium, In.
59. Hirschfeld R.M.A., Bowden C.L., Gitlin M.J., et al. American Psychiatric Association practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159(Suppl):1-50.
60. Holsboer F. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995, 62:340-347.
61. Hughes J.H., Dunne F., Young A.H. Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium. Br J Psychiatry 2000, 177:447-451.
62. Judd L.J., Akiskal H.S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003, 73:123-131.
63. Judd L.L., Schettler P.J., Endicott J., et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59:530-537.
64. Judd L.L.M.D., Akiskal H.S., Schettler P.J., et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003, 60:261-269.
65. Keck P.E., Calabrese J.R., McQuade R.D., et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006, 67:626-637.
66. Kieseppa T., Partonen T., Houkka J., et al. High concordance of bipolar I disorder in a nationwide sample of twins. Am J Psychiatry 2004, 161:1814-1821.
67. Koenig F., Gruenewald I., Petersdorff T., et al. Combined therapy using SSRIs with neuroleptics in delusional depression (abstract) 1998, Annual Meeting of the American Psychiatric Association, Toronto, Ontario, In.
68. Krishnan K.R.R., McDonald W.M., Escalona P.R., et al. Magnetic resonance imaging of the caudate nuclei in depression. Arch Gen Psychiatry 1992, 49:553-557.
69. Lam D. A randomized controlled study of cognitive therapy of relapse prevention for bipolar affective disorder: outcome of the first year. Bipolar Disord 2002, 4:104.
70. Lambert D.B.J., Hamshere M.L., Seguardo R., et al. The Wellcome Trust Ireland/UK bipolar disorder sibling pair study: stage II analysis (abstract). Am J Med Genet 2004, 130B:51.
71. Lewis L. A consumer perspective concerning the diagnosis and treatment of bipolar disorder. Biol Psychiatry 2000, 48:442-444.
72. Lowrey P.L., Shimomura K., Antoch M.P., et al. Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau. Science 2000, 288:483-491.
73. Lyoo I.K., Kim M.J., Stoll A.L., et al. Frontal lobe gray matter density decreases in bipolar I disorder. Biol Psychiatry 2004, 55:648-651.
74. Manji H.K., Zarate C.A. Molecular and cellular mechanism underlying mood stabilisation in bipolar disorder: implications for the development of improved therapeutics. Mol Psychiatry 2002, 7:s1S7.
75. Martinot J.L., Feline A., Huret J.D., et al. Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am J Psychiatry 1990, 147:1313-1317.
76. McGuffin P., Katz R., Bebbington P. Hazard, heredity and depression. A family study. J Psychiatr Res 1987, 21:365-375.
77. Miklowitz D., Craighead W. Bipolar affective disorder: Does psychosocial treatment add to the efficacy of drug therapy?. TEN 2001, 3:58-64.
78. Miklowitz D., Goldstein M. Bipolar Disorder: A Family-Focused Treatment Approach 1997, Guilford Press, New York.
79. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
80. Nemeroff C.B., Evans D.L., Gyulai L., et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001, 158:906-912.
81. Neves-Pereira M., Mundo E., Muglia P., et al. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 2002, 71:651-655.
82. Newport D.J., Stowe Z.N., Viguera A.C., et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008, 10:432-436.
83. Oswald P., Massat I., Souery D., et al. Non-replication of the brain-derived neurotrophic factor (BDNF) association in bipolar affective disorder: a Belgian patient-control study. Am J Med Genet 2004, 129:34-35.
84. Pariante C.M. The glucocorticoid receptor: part of the solution or part of the problem?. J Psychopharmacol 2006, 20:79-84.
85. Perlis R.H., Miyahara S., Marangell L.B., et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004, 55:875-881.
86. Perlis R.H., Welge J.A., Vornik L.A., et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006, 67:509-516.
87. Post R.M. Sensitization and kindling perspectives for the course of affective illness: toward a new treatment with the anticonvulsant carbamazepine. Pharmacopsychiatry 1990, 23:3-17.
88. Post R. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992, 149:191-201.
89. Post R.M. The transduction of psychosocial stress into the neurobiology of recurrent affective illness. Am J Psychiatry 1992, 149:999-1010.
90. Post R., Denicoff K., Frye M., et al. Long-term outcome of anticonvulsants in affective disorders. Bipolar Disorders: Clinical Course and Outcome 1999, 85-114. American Psychiatric Press, Washington, DC. J. Goldberg, M. Harrow (Eds.).
91. Post R., Altshuler L., Leverich G., et al. Randomized comparison of bupropion, sertraline, and venlafaxine as adjunctive treatment in acute bipolar depression 2004, Annual Meeting of the American Psychiatric Association. New York, In.
92. Quraishi S., Frangou S. Neuropsychology of bipolar disorder: a review. J Affect Disord 2002, 72:209-226.
93. Rapoport S.I., Basselin M., Kim H.W., et al. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 2009, 61:185-209.
94. Sassi R.B., Nicoletti M., Brambilla P., et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002, 329:243-245.
95. Seguardo R., Detera-Wadleigh S.D., Levinson D.F., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am J Hum Genet 2003, 73:49-62.
96. Shah PJ, E.K., Glabus MF, Goodwin G.M Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998, 172:527-532.
97. Shiah I.-S., Yatham L., Lam R., et al. Effects of divalproex sodium on 5-HT1A receptor function in healthy human males: hypothermic, hormonal, and behavioral responses to ipsapirone. Neuropsychopharmacology 1997, 17:382-390.
98. Shink E, M.J., Sherrington R., Barden N A genome-wide scan points to a susceptibility locus for bipolar disorder on chromosome 12. Mol Psychiatry 2005, 10:545-552.
99. Silverstone P.H., Wu R.H., O'Donnell T., et al. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 2003, 18:73-79.
100. Skibinska M., Czerski P.M., Leszczynska-Rodziewicz A., et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder. World J Biol Psychiatry 2004, 5:215-220.
101. Sklar P., Gabriel S.B., McInnes M.G., et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF as a potential risk locus. Mol Psychiatry 2002, 7:579-593.
102. Soares J.C., Mann J.J. The functional neuroanatomy of mood disorders. J Psychiatr Res 1997, 31:393-432.
103. Steffansson H., Sigurdson E., Steinthorsdottir V., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71:877-892.
104. Strakowski S.M., DelBello M.P. Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder?. Bipolar Disord 2002, 4:80-88.
105. Strakowski S.M., Sax K.W., Zimmerman M.E., et al. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch Gen Psychiatry 1999, 56:254-260.
106. Strakowski S.M., Adler C.M., Holland S.K., et al. Abnormal fMRI brain activation in euthymic bipolar disorder patients during a counting Stroop interference task. Am J Psychiatry 2005, 162:1697-1705.
107. Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000, 157:1552-1562.
108. Tohen M., Goodwin F. Epidemiology of bipolar disorder. Textbook in Psychiatric Epidemiology 1995, 301-315. Wiley, New York. M. Tsuang, M. Tohen, G.P. Zahner (Eds.).
109. Tohen M., Vieta E., Calabrese J., et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60:1079-1088.
110. Tohen M., Zarate C.A., Hennen J., et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003, 160:2099-2107.
111. Tohen M., Chengappa K.N., Suppes T., et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004, 184:337-345.
112. Tohen M., Calabrese J.R., Sachs G.S., et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006, 163:247-256.
113. Tondo L., Hennen J., Baldessarini R.J. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003, 108:4-14.
114. Viguera A.C., Nonacs R., Cohen L.S., et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000, 157:179-184.
115. Viguera A.C., Cohen L.S., Baldessarini R.J., et al. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002, 47:426-436.
116. Viguera A.C., Whitfield T., Baldessarini R.J., et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007, 164:1817-1824. quiz 1923.
117. Watson S., Gallagher P., Ritchie J.C., et al. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004, 184:496-502.
118. Wehr T.A., Goodwin F.K. Can antidepressants cause mania and worsen the course of affective illness?. Am J Psychiatry 1987, 144:1403-1411.
119. Wehr T.A., Sack D.A., Rosenthal N.E., et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988, 145:179-184.
120. Winsberg M.E., Sachs N., Tate D.L., et al. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 2000, 47:475-481.
121. International Statistical Classification of Diseases and Related Health Problems 1992, World Health Organization, World Health Organization, Geneva. 10th revision.
122. Yildiz-Yesiloglu A., Ankerst D.P. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:969-995.
123. Zhou J.N., Riemersma R.F., Riemersma R.F., Unmehopa U.A., et al. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001, 58:655-662.
124. Zobel A., Schulze-Rauschenbach S., von Widdern O., et al. High neuroticism and depressive temperament are associated with dysfunctional regulation of the hypothalamic-pituitary-adrenocortical system in healthy volunteers. Acta Psychiatr Scand 2004, 109:392-399.